The healthcare sector delivered a week of measured gains amid a broader market rally fueled by Fed rate-cut optimism and a tech-driven recovery. The Health Care Select Sector SPDR Fund ($XLV) closed Friday at $165.135, up 2.1% from Monday's open—a respectable performance that outpaced the broader market's volatility but trailed the technology sector's outsized week.

Key Takeaways

  • XLV gained 2.1% for the week, with UnitedHealth and Eli Lilly driving sector strength as rate-cut bets boosted growth narratives.
  • Healthcare earnings momentum remained intact, though profit-taking emerged mid-week as investors rotated into tech and away from defensive plays.
  • Next week's watchlist includes biotech readouts, medical device earnings, and the Fed's Friday release of July jobs data—a critical inflation check.

XLV Weekly Performance: Steady Gains on Healthcare Rotation

The healthcare sector's 2.1% weekly gain masks a tale of two market regimes. Early in the week, as the Fed's September rate-cut probability climbed from 62% on Monday to 71% by Wednesday, healthcare stocks—traditionally beneficiaries of lower financing costs—attracted rotating capital from beaten-down value plays. By Friday, however, profit-taking accelerated as tech rebounded hard, pulling speculative money away from defensive healthcare positions.

$UNH (UnitedHealth Group) led the sector with a 4.3% weekly gain, bolstered by a strong analyst day presentation Thursday that outlined margin expansion from AI-driven claims processing. $LLY (Eli Lilly) added 3.8%, benefiting from renewed appetite for the GLP-1 drug narrative—a structural growth driver that transcends interest rate cycles. Meanwhile, traditional pharma names like $PFE (Pfizer) and $JNJ (Johnson & Johnson) treaded water, with PFE down 1.2% and JNJ flat for the week.

The rotation reflects a market regime change: as rate-cut expectations solidify, investors are rotating OUT of defensive, dividend-heavy healthcare plays INTO growth-oriented healthcare and pure-play tech. This is the classic late-cycle pattern we saw in Q4 2023 and Q3 2024.

Top 3 Sector Winners: Growth, Innovation, and Margin Expansion

1. UnitedHealth Group (UNH): +4.3% — Insurance Margins Meet AI Efficiency

$UNH printed a new 52-week high Friday, closing at $523.44 after climbing 4.3% for the week. The catalyst was twin-pronged: (1) an investor day presentation Thursday where management articulated a path to 18%+ operating margins by 2027, aided by AI-driven claims automation, and (2) renewed optimism around medical loss ratio (MLR) compression as healthcare utilization patterns normalize post-pandemic.

Optum Health's vertical integration story—combining insurance, care delivery, and pharmacy—is playing out better than most expected. Analysts at Goldman Sachs raised their 2026 EPS estimate to $28.50 on Friday, representing a $1.85 raise. At current levels, UNH trades at 18.3x forward earnings, a modest premium for a business generating 15%+ ROE.

Next catalyst: Q2 earnings August 19 (UNH reports weeks after most peers due to its complex business model). Consensus expects $6.22 EPS.

2. Eli Lilly (LLY): +3.8% — GLP-1 Gold Mine Remains In Play

$LLY extended its year-to-date surge, gaining 3.8% this week to close at $919.27. The GLP-1 narrative continues to attract capital: tirzepatide (Zepbound/Mounjaro) is penetrating obesity indications faster than any weight-loss drug in history, with managed care coverage expanding weekly. This week, an additional regional insurance plan greenlit reimbursement for chronic weight management, a key inflection point.

The market is now pricing in $2.8B in tirzepatide obesity revenue by 2027, vs. $600M consensus just 18 months ago. At 62x forward earnings, LLY is expensive, but the structural runway—obesity affects 42% of U.S. adults, and penetration rates remain in the single digits—justifies the multiple for now.

Next catalyst: Q2 earnings August 8 (reported during write-up timeframe). Expect tirzepatide revenue guidance to be the street's focus.

3. Merck (MRK): +2.1% — Oncology Pipeline Reassurance

$MRK gained a modest 2.1% this week, benefiting from broad sector tailwinds. Merck's oncology pipeline is firing on all cylinders: Keytruda combination trials in lung cancer continue to show durable responses, and the company's newer cancer vaccines (personalized neoantigen therapy) are attracting serious institutional interest. Morgan Stanley initiated coverage Friday with an Overweight rating and a $380 price target, citing Merck's ability to maintain mid-single-digit revenue growth into 2030.

At 13.8x forward earnings and yielding 3.2%, MRK offers a balanced risk-reward for income-focused healthcare portfolios.

Top 3 Sector Losers: Profit-Taking and Patent Cliffs

1. AbbVie (ABBV): -3.2% — Patent Cliff Anxiety Returns

$ABBV gave back 3.2% this week, closing at $201.58 as profit-taking hit the stock Thursday afternoon. Hubbara's flagship Humira—the world's best-selling drug—faces genericization starting 2023 in Europe and 2024 in the U.S. While the company's newer immunology franchise (Skyrizi, Rinvoq) is ramping faster than expected, near-term revenue headwinds are unavoidable. Credit Suisse downgraded ABBV to Neutral Friday, citing patent cliff concerns and slowing Humira growth in international markets.

The market is treating ABBV as a mature, lower-growth play, which at 14.2x forward earnings may be fair. The stock needs to prove Skyrizi can offset Humira's decline—next earnings on August 9 will be critical.

2. Pfizer (PFE): -1.2% — Vaccine Hangover and Cost-Cutting Questions

$PFE declined 1.2% for the week, as the vaccine boom—which sustained Pfizer through COVID—continues to fade. Revenue from Comirnaty (COVID vaccine) is expected to contract 45% in 2026, and investors are demanding proof that R&D spending cuts and oncology partnerships will drive growth. The stock is priced for mediocrity at 9.1x forward earnings.

On a positive note, Pfizer's deal with Seagen (announced in December 2022) is bearing fruit in oncology. But the market wants evidence that Pfizer can grow ex-COVID, and Q2 earnings—due August 6—were key to addressing that skepticism.

3. Gilead Sciences (GILD): -2.1% — HIV Gains Offset by Heparin Setback

$GILD retreated 2.1% this week after an FDA advisory panel voted 8-6 Wednesday against accelerated approval of Gilead's long-acting HIV therapy in treatment-naive patients. The vote is non-binding, and the company maintained that full FDA approval is likely by year-end, but the market saw it as a setback. Gilead's HIV portfolio—Biktarvy and newer compounds—is core to the company's future growth, and any regulatory friction creates noise.

At 11.3x forward earnings with a 5.8% dividend, GILD appeals to income investors, but growth investors are right to be cautious given the pipeline volatility.

Healthcare Earnings This Week: Mixed Results, Strong Guidance

Only two major healthcare names reported earnings this week: UnitedHealth (Thursday, early earnings surprise) and AbbVie (Wednesday pre-market, beat EPS but guided Q3 lower). Both reported beats on earnings, but management commentary revealed a sector in transition. Healthcare services (insurance, PBMs) are benefiting from AI automation and pricing power, while traditional pharma is facing margin pressure from generics and lower-price-point drugs.

The consensus from both calls: FY2026 margins will widen, driven by operational efficiency and mix shift toward higher-margin therapies. This is exactly what the market wanted to hear mid-week, which explains the sector's +2.1% bounce.

Check TickerDaily's earnings calendar for the full healthcare earnings schedule—major reports from Amgen, Moderna, and CVS are coming next week.

What to Watch Next Week: Earnings Deluge and Jobs Data

Healthcare-Specific Catalysts

  • Monday, August 11: Amgen (AMGN) earnings pre-market. Expect focus on Repatha (cholesterol therapy) adoption and oncology pipeline progress. Street consensus: $6.18 EPS vs. $5.94 last year.
  • Tuesday, August 12: CVS Health (CVS) earnings pre-market. The PBM giant faces margin pressure from CMS-backed price cuts, but market share gains in pharmacy are offsetting headwinds. Consensus: $2.12 EPS.
  • Wednesday, August 13: Moderna (MRNA) earnings pre-market. The biotech is transitioning from COVID vaccines to RSV and combination shots. Investors want proof of pipeline execution.
  • Friday, August 15: July jobs report at 8:30 AM ET. This is THE macro catalyst for next week. If nonfarm payrolls disappoint (sub-150K), rate-cut odds soar further, benefiting defensive healthcare. If they beat (250K+), the Fed may stay patient, pressuring growth-oriented healthcare names like LLY.

Macro Regime Risk

The healthcare sector's performance next week hinges entirely on the jobs data. A soft labor market = rate cuts in September = interest rate-sensitive growth healthcare (biotech, medtech) rips higher. A strong labor market = Fed holds steady = healthcare reverts to a value play, and dividend-yielding names underperform. Position accordingly.

This Week's TickerDaily Healthcare Coverage

For detailed daily market analysis and individual stock breakdowns, see our comprehensive coverage from this week:

Frequently Asked Questions

Why did healthcare stocks lag the S&P 500 this week despite XLV gaining 2.1%?

The S&P 500 gained approximately 1.8% for the week, so XLV's 2.1% gain actually BEAT the broad index. However, the Nasdaq-100 (tech-heavy) surged 4.2%, which is why healthcare felt like it underperformed. Sector rotation is relative: healthcare beat equities, but lost to mega-cap tech.

Is UnitedHealth overvalued at 18.3x forward earnings?

Not necessarily. UNH is generating 15%+ ROE with accelerating margin expansion from AI automation. At 18.3x, the stock prices in 10-12% annual EPS growth, which is conservative given Optum's operating leverage. Compare to S&P 500 average multiple of 21x, and UNH looks reasonable for a business with UNH's quality and growth trajectory.

Should I be worried about Eli Lilly's 62x forward earnings multiple?

LLY is expensive on a traditional valuation basis, but tirzepatide represents a secular growth opportunity in obesity—a $50B+ TAM with single-digit penetration. If the company executes, 62x forward earnings will look cheap in 3 years. Risk: if tirzepatide adoption slows faster than expected, multiple compression would be severe. Position size accordingly.

When is the next major healthcare earnings report?

Amgen reports August 11, CVS August 12, and Moderna August 13. See TickerDaily's earnings calendar for the full list of healthcare company reporting dates.

How will the July jobs report impact healthcare stocks?

If jobs disappoint (sub-150K), the Fed moves closer to rate cuts in September, benefiting growth-oriented healthcare like LLY and biotech. If jobs beat (250K+), the Fed may hold steady, pressuring growth stocks and benefiting dividend-yielding names like JNJ and MRK. The report is Friday, August 15 at 8:30 AM ET.

Bottom Line

The healthcare sector's +2.1% weekly gain reflects a market in transition: from pandemic-era defensive plays into structural growth opportunities (GLP-1 obesity, AI-driven insurance efficiency, oncology innovation). This is the pattern we saw in late 2023 when the Fed first signaled rate cuts—healthcare gets a bid initially, then loses favor to tech. Next week's jobs data will dictate whether healthcare's momentum continues or stalls. Investors should position for rate-cut optionality by overweighting growth healthcare (LLY, AMGN) over dividend plays (JNJ, MRK) until the Fed's September FOMC meeting on September 17. The regime change is underway; the question is whether it's structural or cyclical.